The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border

Alice Hernandez Grant, Yoshira Marie Ayala-Marin, Jonathon Edward Mohl, Elisa Robles-Escajeda, Georgialina Rodriguez, Julie Dutil and Robert Arthur Kirken
Additional contact information
Alice Hernandez Grant: Department of Biological Sciences, College of Science, The University of Texas at El Paso, El Paso, TX 79968, USA
Yoshira Marie Ayala-Marin: Department of Biological Sciences, College of Science, The University of Texas at El Paso, El Paso, TX 79968, USA
Jonathon Edward Mohl: Department of Mathematical Sciences, College of Science, The University of Texas at El Paso, El Paso, TX 79968, USA
Elisa Robles-Escajeda: Department of Biological Sciences, College of Science, The University of Texas at El Paso, El Paso, TX 79968, USA
Georgialina Rodriguez: Department of Biological Sciences, College of Science, The University of Texas at El Paso, El Paso, TX 79968, USA
Julie Dutil: Department of Biochemistry, Cancer Biology Division, Ponce Research Institute, Ponce Health Sciences University, Ponce, PR 00716, USA
Robert Arthur Kirken: Department of Biological Sciences, College of Science, The University of Texas at El Paso, El Paso, TX 79968, USA

IJERPH, 2021, vol. 18, issue 14, 1-11

Abstract: Next-generation sequencing (NGS) has identified unique biomarkers yielding new strategies in precision medicine for the treatment of Acute lymphoblastic leukemia (ALL). Hispanics show marked health disparities in ALL, often absent in clinical trials or cancer research. Thus, it is unknown whether Hispanics would benefit equally from curated data currently guiding precision oncology. Using whole-exome sequencing, nine ALL patients were screened for mutations within genes known to possess diagnostic, prognostic and therapeutic value. Genes mutated in Hispanic ALL patients from the borderland were mined for potentially pathogenic variants within clinically relevant genes. KRAS G12A was detected in this unique cohort and its frequency in Hispanics from the TARGET-ALL Phase II database was three-fold greater than that of non-Hispanics. STAT5B N642H was also detected with low frequency in Hispanic and non-Hispanic individuals within TARGET. Its detection within this small cohort may reflect a common event in this demographic. Such variants occurring in the MAPK and JAK/STAT pathways may be contributing to Hispanic health disparities in ALL. Notable variants in ROS1 , WT1 , and NOTCH2 were observed in the ALL borderland cohort, with NOTCH2 C19W occurring most frequently. Further investigations on the pathogenicity of these variants are needed to assess their relevance in ALL.

Keywords: ALL; relapse; precision medicine; Hispanic health disparities; KRAS; STAT5B; NOTCH2; ROS1; WT1 (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/14/7345/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/14/7345/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:14:p:7345-:d:591333

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().